In the latest trading session, 1.39 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.80. With the company’s most recent per share price at $6.67 changed hands at -$0.27 or -3.89% at last look, the market valuation stands at $1.94B. RXRX’s current price is a discount, trading about -135.98% off its 52-week high of $15.74. The share price had its 52-week low at $4.97, which suggests the last value was 25.49% up since then. When we look at Recursion Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 4.26 million shares, with the 3-month average coming to 4.90 million.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.35.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in red as seen in intraday trades today. With action -0.74%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.35%, with the 5-day performance at -0.74% in the red. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -1.91% down. Looking at the short shares, we see there were 62.58 million shares sold at short interest cover period of 12.15 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 39.36% from its recent market value. According to analyst projections, RXRX’s forecast low is 6 with 12 as the target high. To hit the forecast high, the stock’s price needs a -79.91% plunge from its current level, while the stock would need to tank 10.04% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Data shows that the Recursion Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.24% over the past 6 months, a 0.00% in annual growth rate that is considerably lower than the industry average of 17.50%. Year-over-year growth is forecast to reach 54.80% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 29.84M. 7 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the current quarter will be 14.6M. The company’s revenue for the corresponding quarters a year ago was 10.53M and 10.89M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 183.30%. The estimates for the next quarter sales put growth at 34.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.41%. The 2024 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 1.11%, but the outlook for the next 5-year period is at 12.00% per year.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.45% of Recursion Pharmaceuticals Inc shares while 88.57% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 92.69%. There are 88.57% institutions holding the Recursion Pharmaceuticals Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 11.924% of the shares, roughly 28.14 million RXRX shares worth $211.07 million.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30.
